| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.014 | 0.6 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |